Rigel Pharmaceuticals

NASDAQ:RIGL

18.88

-0.72 (-3.67%)

4:34:11 PM EDT: $18.82 -0.06 (-0.32%)

Market Cap (Intraday)	337.44M
Current PE	9.08
Forward PE	16.86
2yr Forward PE	11.8

See more stats

Estimates Current Quarter

Revenue	$48.14 Million
Adjusted EPS	$0.19

See more estimates

10-Day MA	$19.01
50-Day MA	$19.50
200-Day MA	$19.18

See more pivots

Rigel Pharmaceuticals Stock, NASDAQ:RIGL

611 Gateway Boulevard, Suite 900, South San Francisco, California 94080-1985

United States of America

Phone: +1.650.624.1100

Number of Employees: 164

http://www.rigel.com

Description

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.